Med Inspire SA
Med Inspire reported total assets of 18,200 € at the end of the 2025 financial year (annual accounts filed with the NBB on 21 Jul 2026).
The score of Med Inspire shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -94 % Total assets -91 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Med Inspire's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −41,387 € | ||||
| Equity | 10,864 € | ||||
| Cash | 2,547 € | ||||
| EBITDA | −36,766 € | ||||
| Total assets | 18,200 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 21 Jul 2026
- Year ended 31 Dec 2024filed on 17 Jul 2025
- Year ended 31 Dec 2023filed on 25 Jul 2024
- Year ended 31 Dec 2022filed on 22 Jul 2023
- Year ended 31 Dec 2021filed on 02 Jul 2022
Med Inspire's financial analysis
- Solvency59.7%sector median: 32.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Med Inspire
Med Inspire's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0657.885.672
- VAT number
- BE0657885672
- Peppol
- Registered · 0208:0657885672 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 30 Jun 2016
- Registered office
- 1020 Brussels
- Latest accounts
- 2025 · filed on 21 Jul 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Med Inspire (SA) has been based in Brussels since 2016, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net loss of 41,387 € and equity of 10,864 €; its revenue is not published. Its solvency stands at 59.7%, above the median of its sector (32.3%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Med Inspire
Companies in the same business, of comparable size and area, outside its group.
- Biocon Biologics Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €1.09m
- Ofuro Group Wholesale of pharmaceutical and medical goods Zaventem · balance sheet 48,053 €
- Roggen APO Wholesale of pharmaceutical and medical goods Dilbeek · balance sheet 68,518 €
- Endoceutics Wholesale of pharmaceutical and medical goods Brussels · balance sheet €3.45m
- BVPM Distribution Andenne · balance sheet 20,739 €
- Launchpad Europe Wholesale of pharmaceutical and medical goods Oostkamp · balance sheet 120,635 €
- Maimonides Wholesale of pharmaceutical and medical goods Antwerp · balance sheet 142 €
- Wimeq Wholesale of pharmaceutical and medical goods Heusden-Zolder · balance sheet 48,978 €
Frequently asked questions about Med Inspire
What is the revenue of Med Inspire?
Med Inspire files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Med Inspire?
In Belgium, the VAT number is the company number prefixed with BE: BE0657885672 for Med Inspire, if the company is VAT-registered. Its company number (CBE) is 0657.885.672.
Where is the registered office of Med Inspire?
According to the CBE register, the registered office of Med Inspire is in 1020 Brussels.
What is the equity of Med Inspire?
At the close of the 2025 financial year, the equity of Med Inspire amounts to 10,864 €, a solvency of 59.7% of total assets.
Who manages Med Inspire?
The register lists 2 active mandates at Med Inspire. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Med Inspire
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →